(Q43541858)

English

Vaxfectin enhances both antibody and in vitro T cell responses to each component of a 5-gene Plasmodium falciparum plasmid DNA vaccine mixture administered at low doses

scientific article published on 30 October 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Vaxfectin enhances both antibody and in vitro T cell responses to each component of a 5-gene Plasmodium falciparum plasmid DNA vaccine mixture administered at low doses (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Plasmodium falciparum

1 reference

based on heuristic

inferred from title

Thomas L. Richie

9

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

1

object named as

Martha Sedegah

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Jo Glenna Banania

5

object named as

Glenna Banania

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Noelle B Patterson

6

object named as

Noelle B Patterson

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Denise L Doolan

10

object named as

Denise L Doolan

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

4

object named as

Arnel Belmonte

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Marilyn Ferrari

8

object named as

Marilyn Ferrari

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

author name string

William O Rogers

2

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Maria Belmonte

3

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Denis Rusalov

7

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

language of work or name

0 references

publication date

30 October 2009

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

number of pages

11

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

3055-3065

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Immune effector mechanisms in malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

The immunology of malaria infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Gamma-globulin and acquired immunity to human malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Host age as a determinant of naturally acquired immunity to Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Preerythrocytic malaria vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Malaria vaccines and their potential role in the elimination of malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

The future for blood-stage vaccines against malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

A vaccine against malaria: a substantial step forward

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Multi-gene vaccination against malaria: A multistage, multi-immune response approach

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuatedPlasmodium falciparumsporozoite vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Genetically modified Plasmodium parasites as a protective experimental malaria vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Malaria vaccines: the case for a whole-organism approach

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Population structure of the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: implications for vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

NIAID workshop on immunity to malaria: addressing immunological challenges

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Reduced immunogenicity of DNA vaccine plasmids in mixtures

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Transcription status of vaccine candidate genes of Plasmodium falciparum during the hepatic phase of its life cycle

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Clonal conditional mutagenesis in malaria parasites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Vaxfectin enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Improved tuberculosis DNA vaccines by formulation in cationic lipids

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Comparison of the immunological memory after DNA vaccination and protein vaccination against anthrax in sheep

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Vaccination with polymerase chain reaction-generated linear expression cassettes protects mice against lethal influenza A challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Vaxfectin, a cationic lipid-based adjuvant for protein-based influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Effect on antibody and T-cell responses of mixing five GMP-produced DNA plasmids and administration with plasmid expressing GM-CSF.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Induction of multi-antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime/poxvirus boost immunization.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Absence of antigenic competition in Aotus monkeys immunized with Plasmodium falciparum DNA vaccines delivered as a mixture

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Chemical adjuvants for plasmid DNA vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.044

7 January 2021

Identifiers

10.1016/J.VACCINE.2009.10.044

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43541858&oldid=2098201564"